small molecule

AXID

NIZATIDINE

Loss of exclusivityloss of exclusivity
CompanyBraintreeSee this company's full patent-cliff portfolio

Drug detail

Brand nameAXID
Active ingredientNIZATIDINE
Strength15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2004
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AXID patent cliff — loss of exclusivity — | CliffBio